| Year |
Citation |
Score |
| 2024 |
Lara MS, Blakely CM, Riess JW. Targeting MEK in non-small cell lung cancer. Current Problems in Cancer. 101065. PMID 38341356 DOI: 10.1016/j.currproblcancer.2024.101065 |
0.34 |
|
| 2023 |
Caswell DR, Gui P, Mayekar MK, Law EK, Pich O, Bailey C, Boumelha J, Kerr DL, Blakely CM, Manabe T, Martinez-Ruiz C, Bakker B, De Dios Palomino Villcas J, I Vokes N, Dietzen M, et al. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance. Nature Genetics. PMID 38049664 DOI: 10.1038/s41588-023-01592-8 |
0.333 |
|
| 2023 |
He K, Berz D, Gadgeel SM, Iams WT, Bruno DS, Blakely CM, Spira AI, Patel MR, Waterhouse DM, Richards DA, Pham A, Jotte R, Hong DS, Garon EB, Traynor A, et al. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Non-Squamous Non-Small Cell Lung Cancer Progressing On/After Checkpoint Inhibitor Therapy or Chemotherapy. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 36842467 DOI: 10.1016/j.jtho.2023.02.016 |
0.31 |
|
| 2022 |
Noronha A, Belugali Nataraj N, Sang Lee J, Zhitomirsky B, Oren Y, Oster S, Lindzen M, Mukherjee S, Will R, Ghosh S, Simoni-Nieves A, Verma A, Chatterjee R, Borgoni S, Robinson W, ... ... Blakely CM, et al. AXL and error-prone DNA replication confer drug resistance and offer strategies to treat EGFR-mutant lung cancer. Cancer Discovery. PMID 35895872 DOI: 10.1158/2159-8290.CD-22-0111 |
0.307 |
|
| 2022 |
Nanjo S, Wu W, Karachaliou N, Blakely CM, Suzuki J, Chou YT, Ali SM, Kerr DL, Olivas VR, Shue J, Rotow J, Mayekar MK, Haderk F, Chatterjee N, Urisman A, et al. Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer. The Journal of Clinical Investigation. PMID 35579943 DOI: 10.1172/JCI145099 |
0.335 |
|
| 2022 |
Ali M, Lu M, Ang HX, Soderquist RS, Eyler CE, Hutchinson HM, Glass C, Bassil CF, Lopez OM, Kerr DL, Falcon CJ, Yu HA, Hata AN, Blakely CM, McCoach CE, et al. Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Science Translational Medicine. 14: eabc7480. PMID 35353542 DOI: 10.1126/scitranslmed.abc7480 |
0.324 |
|
| 2021 |
Barbosa Rabago D, Blakely CM, Haderk F, Bivona TG. Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids. Journal of Visualized Experiments : Jove. PMID 34866626 DOI: 10.3791/63039 |
0.334 |
|
| 2020 |
Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, ... ... Blakely CM, et al. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell. PMID 32822576 DOI: 10.1016/J.Cell.2020.07.017 |
0.445 |
|
| 2020 |
Gini B, Thomas N, Blakely CM. Impact of concurrent genomic alterations in epidermal growth factor receptor ()-mutated lung cancer. Journal of Thoracic Disease. 12: 2883-2895. PMID 32642201 DOI: 10.21037/Jtd.2020.03.78 |
0.445 |
|
| 2020 |
Ji J, Aredo JV, Piper-Vallillo A, Huppert L, Rotow JK, Husain H, Stewart SL, Cobb R, Wakelee HA, Blakely CM, Wong ML, Gubens MA, Chen J, Oxnard GR, McCoach CE, et al. Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study. Journal of Clinical Oncology. 38: 9570-9570. DOI: 10.1200/Jco.2020.38.15_Suppl.9570 |
0.367 |
|
| 2020 |
Wu W, Okimoto RA, Blakely CM, Fraser J, Bivona TG. Targeted DNA sequencing analysis to reveal genetic diversity and androgen-receptor alteration in advanced EGFR mutant lung adenocarcinoma. Journal of Clinical Oncology. 38: 9526-9526. DOI: 10.1200/Jco.2020.38.15_Suppl.9526 |
0.406 |
|
| 2020 |
Blakely C, Tourneau CL, Lu J, Waqar SN, Huang X, Day B, Simmons B, Barve M. Abstract P3-10-11: Entrectinib in NTRK fusion-positive breast cancer: Integrated analysis of patients enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001 Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-10-11 |
0.443 |
|
| 2019 |
Paz-Ares L, Doebele RC, Farago AF, Liu SV, Chawla SP, Tosi D, Blakely CM, Krauss JC, Sigal D, Bazhenova L, John T, Besse B, Wolf J, Seto T, Chow-Maneval E, et al. Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: ii48-ii49. PMID 32131246 DOI: 10.1093/Annonc/Mdz063.011 |
0.361 |
|
| 2019 |
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. The Lancet. Oncology. PMID 31838007 DOI: 10.1016/S1470-2045(19)30691-6 |
0.303 |
|
| 2019 |
Blakely CM, Riess JW. Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC. Expert Review of Anticancer Therapy. 19: 1061-1075. PMID 31809604 DOI: 10.1080/14737140.2019.1699792 |
0.412 |
|
| 2019 |
Blakely CM. A new pathway emerges to interpret lung cancer genomic alterations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31611281 DOI: 10.1158/1078-0432.Ccr-19-2861 |
0.456 |
|
| 2019 |
Rotow JK, Gui P, Wu W, Raymond VM, Lanman RB, Kaye FJ, Peled N, Fece de la Cruz F, Nadres B, Corcoran RB, Yeh I, Bastian BC, Starostik P, Newsom K, Olivas V, ... ... Blakely CM, et al. Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31548343 DOI: 10.1158/1078-0432.Ccr-19-1667 |
0.422 |
|
| 2019 |
Halliday PR, Blakely CM, Bivona TG. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Current Oncology Reports. 21: 21. PMID 30806814 DOI: 10.1007/S11912-019-0770-X |
0.416 |
|
| 2019 |
Wong ML, Miaskowski C, Smith AK, Boscardin WJ, Cohen HJ, Hurria A, Lam V, Ursem CJ, Blakely CM, Gubens MA, Jahan TM, McCoach CE, Allen GM, Rotow J, Dixit N, et al. Prognostic factors among older adults with advanced non-small cell lung cancer (NSCLC): A multisite cohort study. Journal of Clinical Oncology. 37: 11540-11540. DOI: 10.1200/Jco.2019.37.15_Suppl.11540 |
0.328 |
|
| 2019 |
Skoulidis F, Arbour KC, Hellmann MD, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer J, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, et al. Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer. Journal of Clinical Oncology. 37: 102-102. DOI: 10.1200/Jco.2019.37.15_Suppl.102 |
0.363 |
|
| 2019 |
Doebele R, Paz-Ares L, Farago AF, Liu SV, Chawla SP, Tosi D, Blakely CM, Krauss JC, Sigal D, Bazhenova L, John T, Besse B, Wolf J, Seto T, Chow-Maneval E, et al. Abstract CT131: Entrectinib inNTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct131 |
0.449 |
|
| 2019 |
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Kuhn J, Dumont S, Mccormick F, Goga A, Blakely CM, Bivona TG, Bandyopadhyay S. Abstract 2902: Non-genetic TPX2/AURKA signaling facilitates tumor evolution in EGFR-TKI resistance in NSCLC Cancer Research. 79: 2902-2902. DOI: 10.1158/1538-7445.Am2019-2902 |
0.451 |
|
| 2019 |
Woodard G, Ding V, Kim I, Jones K, Chavez G, Haro G, Kratz J, Mann M, Rotow J, Blakely C, Jablons D. MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.544 |
0.319 |
|
| 2019 |
Rotow J, Urisman A, Mccoach C, Jahan T, Bivona T, Jones K, Gupta A, Do H, Riess J, Aisner D, Doebele R, Jablons D, Kratz J, Blakely C. P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 14. DOI: 10.1016/J.Jtho.2019.08.1209 |
0.353 |
|
| 2019 |
Wu S, Lazar A, Gubens M, Blakely C, Gottschalk A, Garsa A, Jablons D, Jahan T, Wang V, Dunbar T, Paz R, Curran L, Guthrie W, Belkora J, Yom S. The Impact of Structured, Prospective Exposure to the NCCN Guidelines when Making Treatment Decisions: Improved Metrics of Guideline-Concordant Care for Patients with Non-Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 104: 231. DOI: 10.1016/J.Ijrobp.2019.01.015 |
0.324 |
|
| 2018 |
Leal TA, Spira AI, Blakely C, He K, Berz D, Richards D, Uyeki J, Savage A, Roque T, Massarelli E, Jotte RM, Chen I, Christensen J, Olson P, Tassell V, et al. Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii400-viii401. PMID 32137001 DOI: 10.1093/Annonc/Mdy288.002 |
0.313 |
|
| 2018 |
Rotow JK, Woodard GA, Urisman A, McCoach CE, Bivona TG, Elicker BM, Jablons DM, Blakely CM. Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clinical Lung Cancer. PMID 30553716 DOI: 10.1016/J.Cllc.2018.11.003 |
0.315 |
|
| 2018 |
Neel DS, Allegakoen DV, Olivas V, Mayekar MK, Hemmati G, Chatterjee N, Blakely CM, McCoach CE, Rotow JK, Le A, Karachaliou N, Rosell R, Riess JW, Nichols R, Doebele RC, et al. Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins. Cancer Research. PMID 30538120 DOI: 10.1158/0008-5472.Can-18-1492 |
0.329 |
|
| 2018 |
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, ... ... Blakely CM, et al. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nature Medicine. PMID 30478424 DOI: 10.1038/S41591-018-0264-7 |
0.382 |
|
| 2018 |
Blumenthal GM, Bunn PA, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, Carbone DP, Aerts HJWL, Aisner DL, Bergh J, Berry DA, Jarkowski A, Botwood N, Cross DAE, Diehn M, ... ... Blakely CM, et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30268698 DOI: 10.1016/J.Jtho.2018.09.017 |
0.4 |
|
| 2018 |
Nichols RJ, Haderk F, Stahlhut C, Schulze CJ, Hemmati G, Wildes D, Tzitzilonis C, Mordec K, Marquez A, Romero J, Hsieh T, Zaman A, Olivas V, McCoach C, Blakely CM, et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nature Cell Biology. PMID 30104724 DOI: 10.1038/S41556-018-0169-1 |
0.362 |
|
| 2018 |
McCoach CE, Blakely CM, Banks KC, Levy BM, Chue B, Raymond VM, Le A, Lee CE, Diaz J, Waqar SN, Purcell WT, Aisner DL, Davies KD, Lanman RB, Shaw AT, et al. Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29599410 DOI: 10.1158/1078-0432.Ccr-17-2588 |
0.459 |
|
| 2018 |
Rotow J, Wu W, Blakely CM, Lanman RB, Raymond VM, Kaye FJ, Gui P, Fraser J, Wolff A, Collisson EA, McCoach CE, Bivona TG. Concurrent genomic alterations in lung adenocarcinoma with a MET exon 14 skipping mutation. Journal of Clinical Oncology. 36: 9083-9083. DOI: 10.1200/Jco.2018.36.15_Suppl.9083 |
0.316 |
|
| 2018 |
Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Hemmati GG, Krings G, Haringsma HJ, Simmons AD, Harding TC, Goga A, Blakely C, Bivona T, Bandyopadhyay S. Abstract 1957: Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer Cancer Research. 78: 1957-1957. DOI: 10.1158/1538-7445.Am2018-1957 |
0.455 |
|
| 2018 |
Shah K, Blakely C, Bivona T, Bandyopadhyay S. P1.13-10 Aurora Kinase A Drives the Evolution of Resistance to Third Generation EGFR Inhibitors in Lung Cancer Journal of Thoracic Oncology. 13: S585-S586. DOI: 10.1016/J.Jtho.2018.08.867 |
0.383 |
|
| 2018 |
Rotow J, Mccoach C, Maynard A, Naeger D, Gesthalter Y, Kolli K, Darmanis S, Bivona T, Blakely C, Weissman J. MA11.09 Single-Cell Characterization of the Immunologic Microenvironment in Advanced-Stage, Oncogene-Driven NSCLC Journal of Thoracic Oncology. 13: S395. DOI: 10.1016/J.Jtho.2018.08.409 |
0.328 |
|
| 2018 |
Woodard G, Wang S, Kratz J, Haro G, Gubens M, Blakely C, Jahan T, Jones K, Mann M, Jablons D. P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy Journal of Thoracic Oncology. 13. DOI: 10.1016/J.Jtho.2018.08.1487 |
0.33 |
|
| 2017 |
Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, et al. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics. PMID 29106415 DOI: 10.1038/Ng.3990 |
0.477 |
|
| 2017 |
Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clinical Lung Cancer. PMID 28645632 DOI: 10.1016/J.Cllc.2017.05.015 |
0.418 |
|
| 2017 |
Jonsson VD, Blakely CM, Lin L, Asthana S, Matni N, Olivas V, Pazarentzos E, Gubens MA, Bastian BC, Taylor BS, Doyle JC, Bivona TG. Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Scientific Reports. 7: 44206. PMID 28287179 DOI: 10.1038/Srep44206 |
0.437 |
|
| 2017 |
Antonia SJ, Brahmer JR, Balmanoukian AS, Kim D, Kim S, Ahn M, Jamal R, Jaeger D, Ott PA, Ascierto PA, Gregorc V, Goldman JW, Blakely CM, Jin X, Antal J, et al. Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E20504 |
0.342 |
|
| 2017 |
Blakely CM, Wu W, Gubens MA, Rotow J, Wang V, Banks K, Lanman RB, Mack PC, Husain H, McCoach CE, Doebele RC, Riess J, Bivona TG. Evolution and clinical impact of genomic alterations detectable in circulating tumor DNA of 1150 advanced EGFR-mutant (mt) lung cancer patients. Journal of Clinical Oncology. 35: 9009-9009. DOI: 10.1200/Jco.2017.35.15_Suppl.9009 |
0.436 |
|
| 2017 |
Drilon A, Sankhala KK, Liu SV, Cho BC, Blakely C, Chee CE, Fakih M, Polikoff J, Hornby Z, Schechet L, Luo D, Maneval EC, Multani PS, Doebele RC. Abstract CT060: STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct060 |
0.427 |
|
| 2017 |
Yang J, Reckamp K, Kim Y, Novello S, Smit E, Lee J, Su W, Akerley W, Blakely C, Bazhenova L, Chiari R, Hsia T, Golsorkhi T, Despain D, Shih D, et al. P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC) Journal of Thoracic Oncology. 12: S2397. DOI: 10.1016/J.Jtho.2017.11.013 |
0.375 |
|
| 2017 |
Woodard G, Crockard J, Zoon-Besselink C, Kratz J, Gubens M, Jahan T, Blakely C, Jones K, Mann M, Jablons D. OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2016.11.341 |
0.38 |
|
| 2017 |
Werner T, Heist R, Carvajal R, Adkins D, Alva A, Goel S, Hong D, Bazhenova L, Saleh M, Siegel R, Kyriakopoulos C, Blakely C, Eaton K, Lauer R, Wang D, et al. P2.06-001 A Study of MGCD516, a Receptor Tyrosine Kinase (RTK) Inhibitor, in Molecularly Selected Patients with NSCLC or Other Advanced Solid Tumors Journal of Thoracic Oncology. 12: S1068-S1069. DOI: 10.1016/J.Jtho.2016.11.1494 |
0.367 |
|
| 2016 |
Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, et al. Inactivation of Capicua drives cancer metastasis. Nature Genetics. PMID 27869830 DOI: 10.1038/Ng.3728 |
0.447 |
|
| 2016 |
McCoach CE, Bivona TG, Blakely CM, Doebele RC. Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clinical Lung Cancer. PMID 27378174 DOI: 10.1016/J.Cllc.2016.05.025 |
0.438 |
|
| 2016 |
Yang JC, Popat S, Novello S, Groen HJ, Perol M, Felip E, Griesinger F, Reckamp KL, Lee J, Smit EF, Blakely CM, Akerley WL, Kim Y, Bazhenova L, Califano R, et al. TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy. Journal of Clinical Oncology. 34: TPS9106-TPS9106. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps9106 |
0.374 |
|
| 2016 |
Rybkin II, Kio EA, Masood A, Shum MK, Halmos B, Blakely CM, Eaton KD, Sharma N, Nemunaitis JJ, Saccaro SJ, Boumber Y, Mena RR, Mirshahidi HR, Janne PA, Christensen J, et al. Amethyst NSCLC trial: Phase 2, parallel-arm study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) with activating genetic alterations in mesenchymal-epithelial transition factor (MET). Journal of Clinical Oncology. 34: TPS9099-TPS9099. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps9099 |
0.4 |
|
| 2016 |
Blakely CM, Banks KC, Lanman RB, Riess J, Mack PC, Bivona TG. Circulating tumor DNA sequencing to reveal the genomic complexity of advanced EGFR-mutant lung adenocarcinoma. Journal of Clinical Oncology. 34: e23079-e23079. DOI: 10.1200/Jco.2016.34.15_Suppl.E23079 |
0.396 |
|
| 2016 |
Ihuegbu N, Banks KC, Fairclough SR, Zill OA, Chudova D, Lanman RB, Blakely CM. Non-invasive detection of crizotinib resistance in ALK-rearranged lung adenocarcinoma directs treatment with next-generation ALK inhibitors. Journal of Clinical Oncology. 34: e20643-e20643. DOI: 10.1200/Jco.2016.34.15_Suppl.E20643 |
0.339 |
|
| 2016 |
Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, ... ... Blakely C, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0173-6 |
0.317 |
|
| 2015 |
Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nature Medicine. 21: 1038-47. PMID 26301689 DOI: 10.1038/Nm.3930 |
0.385 |
|
| 2015 |
Blakely CM, Pazarentzos E, Olivas V, Asthana S, Yan JJ, Tan I, Hrustanovic G, Chan E, Lin L, Neel DS, Newton W, Bobb KL, Fouts TR, Meshulam J, Gubens MA, et al. NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer. Cell Reports. 11: 98-110. PMID 25843712 DOI: 10.1016/J.Celrep.2015.03.012 |
0.435 |
|
| 2014 |
Blakely CM, Pazarentzos E, Asthana S, Olivas V, Tan I, Fouts T, Meshulam J, Bivona TG. Abstract 1836: Erlotinib induces NF-kappa B dependence that promotes EGFR tyrosine kinase inhibitor resistance in lung adenocarcinoma Cancer Research. 74: 1836-1836. DOI: 10.1158/1538-7445.Am2014-1836 |
0.397 |
|
| 2013 |
Blakely CM, Lin L, Asthana S, Sidiropoulos N, Nelson T, Bastian BC, Gubens MA, Taylor BS, Bivona TG. Concurrent driver mutations in non-small cell lung cancer (NSCLC) patients (p) on targeted therapy uncovered by comprehensive molecular profiling. Journal of Clinical Oncology. 31: 11004-11004. DOI: 10.1200/Jco.2013.31.15_Suppl.11004 |
0.391 |
|
| 2013 |
Blakely C, Bose T, Wheeler M, Bueno R, Sugarbaker D, Jablons D, Broaddus VC, Coussens L. Abstract 4723: Macrophages foster neoplastic progression of malignant mesothelioma and limit response to chemotherapy. Cancer Research. 73: 4723-4723. DOI: 10.1158/1538-7445.Am2013-4723 |
0.412 |
|
| 2013 |
Blakely CM, Olivas V, Zhang J, Bivona TG. Abstract 4631: Pharmacologic inhibition of NF-kappaB overcomes de novo resistance to erlotinib in models of EGFR-mutant lung adenocarcinoma. Cancer Research. 73: 4631-4631. DOI: 10.1158/1538-7445.Am2013-4631 |
0.469 |
|
| 2012 |
Blakely CM, Bivona TG. Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discovery. 2: 872-5. PMID 23071030 DOI: 10.1158/2159-8290.Cd-12-0387 |
0.402 |
|
| 2012 |
Broaddus VC, Battula S, Barbone D, Blakely C, Sugarbaker DJ, Bueno R, Coussens LM. Abstract LB-251: Manipulation of macrophage phenotype enhances the apoptotic response to chemotherapy in mesothelioma Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-251 |
0.364 |
|
| 2011 |
Blakely C, Jahan T. Emerging antiangiogenic therapies for non-small-cell lung cancer. Expert Review of Anticancer Therapy. 11: 1607-1618. PMID 21999134 DOI: 10.1586/Era.11.146 |
0.396 |
|
| 2011 |
Blakely CM, Kolhatkar N, Johansson M, Beltran A, Barbone D, Bueno R, Sugarbaker D, Jahan T, Jablons D, Broaddus VC, Coussens LM. Abstract 454: Targeting macrophages in a preclinical model of malignant mesothelioma Cancer Research. 71: 454-454. DOI: 10.1158/1538-7445.Am2011-454 |
0.445 |
|
| 2011 |
Blakely CM, Kolhatkar N, Johansson M, Hainer CM, Wheeler M, Yagui-Beltran A, Bueno R, Sugarbaker DJ, Jahan TM, West BL, Jablons DM, Broaddus VC, Coussens LM. Abstract C231: Colony-stimulating factor-1 receptor blockade reprograms malignant mesothelioma tumor microenvironments and decreases tumor growth. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C231 |
0.425 |
|
| 2006 |
Blakely CM, Stoddard AJ, Belka GK, Dugan KD, Notarfrancesco KL, Moody SE, D'Cruz CM, Chodosh LA. Hormone-induced protection against mammary tumorigenesis is conserved in multiple rat strains and identifies a core gene expression signature induced by pregnancy. Cancer Research. 66: 6421-31. PMID 16778221 DOI: 10.1158/0008-5472.Can-05-4235 |
0.713 |
|
| 2005 |
Blakely CM, Sintasath L, D'Cruz CM, Hahn KT, Dugan KD, Belka GK, Chodosh LA. Developmental stage determines the effects of MYC in the mammary epithelium. Development (Cambridge, England). 132: 1147-60. PMID 15689376 DOI: 10.1242/Dev.01655 |
0.736 |
|
| 2005 |
Blakely C, Moody S, Stoddard A, Tombler E, Liu C, Chodosh L. Molecular approaches to understanding pregnancy-induced protection against breast cancer Breast Cancer Research. 7: 1-1. DOI: 10.1186/Bcr1055 |
0.733 |
|
| 2003 |
Chodosh L, Boxer R, Moody S, Keister B, Sarkisian C, Jang J, Belka G, Blakely C, Portocarero C, Sterner C, Notarfrancesco K, Kauh E. Reversibility and progression in conditional transgenic mouse models of breast cancer Breast Cancer Research. 5: 5-5. DOI: 10.1186/Bcr664 |
0.616 |
|
| Show low-probability matches. |